Skip to main content

ALS

7
Pipeline Programs
15
Companies
17
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 17 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Tanabe Pharma America
Tanabe Pharma AmericaNJ - Jersey City
3 programs
3
MT-1186Phase 3
MT-1186Phase 3
MT-1186Phase 3
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Ranolazine 500 MGPhase 21 trial
Active Trials
NCT03472950Completed14Est. Dec 2022
WaVe Life Sciences
WaVe Life SciencesJapan - Kagoshima
2 programs
2
WVE-004Phase 1/21 trial
WVE-004Phase 1/21 trial
Active Trials
NCT05683860Terminated8Est. Jun 2023
NCT04931862Terminated35Est. Jun 2023
ITB Med
ITB MedNY - New York
1 program
1
TCD601Phase 11 trial
Active Trials
NCT06453668Terminated7Est. Jul 2026
Biogen
BiogenCAMBRIDGE, MA
2 programs
Genomic Translation for Amyotrophic Lateral Sclerosis CareN/A1 trial
[11C]-PBR28PHASE_11 trial
Active Trials
NCT02795897Completed254Est. Jun 2022
NCT04490096Terminated2Est. Mar 2022
Providence Therapeutics
1 program
ALS/MND Natural History Study Data RepositoryN/A1 trial
Active Trials
NCT05966038Recruiting5,000Est. Dec 2030
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
ALS/MND Natural History Study Data RepositoryN/A
Clene
CleneSALT LAKE CITY, UT
1 program
CNM-Au8N/A1 trial
Active Trials
NCT06408727Temporarily Not Available
MediciNova
MediciNovaLA JOLLA, CA
1 program
MN-166N/A1 trial
Active Trials
NCT06743776No Longer Available
Biosensics
BiosensicsMA - Newton
1 program
PAMSys Activity Monitoring SystemN/A1 trial
Active Trials
NCT05271435Completed20Est. Jun 2026
Calico
CalicoLONG BEACH, CA
1 program
FosigotifatorPHASE_11 trial
Active Trials
NCT04948645Terminated31Est. Jul 2025
Ultragenyx Pharmaceutical
1 program
TriheptanoinPHASE_1_21 trial
Active Trials
NCT03506425Completed15Est. Mar 2019
Teva
TevaIsrael - Petach Tikva
1 program
TalampanelPHASE_24 trials
Active Trials
NCT00964730Completed135Est. Feb 2010
NCT00696332Completed559Est. May 2010
NCT00036296Completed22Est. Feb 2007
+1 more trials
Genentech
GenentechCA - Oceanside
1 program
TocilizumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT02469896Completed22Est. Jul 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Kite PharmaRanolazine 500 MG
GenentechTocilizumab
TevaTalampanel
TevaTalampanel
WaVe Life SciencesWVE-004
WaVe Life SciencesWVE-004
Ultragenyx PharmaceuticalTriheptanoin
TevaTalampanel
ITB MedTCD601
CalicoFosigotifator
Biogen[11C]-PBR28
TevaTalampanel
BiosensicsPAMSys Activity Monitoring System
BiogenGenomic Translation for Amyotrophic Lateral Sclerosis Care
Providence TherapeuticsALS/MND Natural History Study Data Repository

Clinical Trials (17)

Total enrollment: 6,314 patients across 17 trials

NCT03472950Kite PharmaRanolazine 500 MG

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Start: Jun 2018Est. completion: Dec 202214 patients
Phase 2Completed
NCT02469896GenentechTocilizumab

A Trial of Tocilizumab in ALS Subjects

Start: Nov 2015Est. completion: Jul 201822 patients
Phase 2Completed
NCT00696332TevaTalampanel

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Start: Sep 2008Est. completion: May 2010559 patients
Phase 2Completed
NCT00034814TevaTalampanel

Multicenter Trial for Adults With Partial Seizures

Start: Jan 2002Est. completion: Jan 2006190 patients
Phase 2Completed
NCT05683860WaVe Life SciencesWVE-004

Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

Start: Dec 2022Est. completion: Jun 20238 patients
Phase 1/2Terminated
NCT04931862WaVe Life SciencesWVE-004

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Start: Jun 2021Est. completion: Jun 202335 patients
Phase 1/2Terminated
NCT03506425Ultragenyx PharmaceuticalTriheptanoin

A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)

Start: Jun 2018Est. completion: Mar 201915 patients
Phase 1/2Completed
NCT00036296TevaTalampanel

Effects of Talampanel on Patients With Advanced Parkinson's Disease

Start: Dec 2006Est. completion: Feb 200722 patients
Phase 1/2Completed
NCT06453668ITB MedTCD601

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Start: Apr 2024Est. completion: Jul 20267 patients
Phase 1Terminated
NCT04948645CalicoFosigotifator

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

Start: Sep 2021Est. completion: Jul 202531 patients
Phase 1Terminated
NCT04490096Biogen[11C]-PBR28

Multimodal Imaging Outcome Measures for ALS (Image ALS)

Start: Feb 2021Est. completion: Mar 20222 patients
Phase 1Terminated
NCT00964730TevaTalampanel

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

Start: Oct 2009Est. completion: Feb 2010135 patients
Phase 1Completed
NCT06743776MediciNovaMN-166

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

N/ANo Longer Available
NCT06408727CleneCNM-Au8

Intermediate Expanded Access Protocol CNMAu8.EAP04

N/ATemporarily Not Available
NCT05271435BiosensicsPAMSys Activity Monitoring System

Digital Tools for Assessment of Motor Functions and Falls in ALS

Start: Oct 2021Est. completion: Jun 202620 patients
N/ACompleted
NCT02795897BiogenGenomic Translation for Amyotrophic Lateral Sclerosis Care

Genomic Translation for Amyotrophic Lateral Sclerosis Care

Start: Jun 2016Est. completion: Jun 2022254 patients
N/ACompleted
NCT05966038Providence TherapeuticsALS/MND Natural History Study Data Repository

ALS/MND Natural History Study Data Repository

Start: Apr 2015Est. completion: Dec 20305,000 patients
N/ARecruiting

Related Jobs

Senior Manager, Clinical Data Management

Amylyx PharmaceuticalsAmylyx Pharmaceuticals
Cambridge, MA
18h ago
$156K - $175K/yr

Associate Director, Clinical Data Programmer

Amylyx PharmaceuticalsAmylyx Pharmaceuticals
Cambridge, MA
18h ago
$188K - $211K/yr

Accounts Payable Specialist

Amylyx PharmaceuticalsAmylyx Pharmaceuticals
Cambridge, MA
Yesterday
$65K - $73K/yr

Associate Director, Pricing and Access Analytics

Amylyx PharmaceuticalsAmylyx Pharmaceuticals
Cambridge, MA
3d ago
$182K - $205K/yr

Director, Access Marketing

Amylyx PharmaceuticalsAmylyx Pharmaceuticals
Cambridge, MA
3d ago
$224K - $252K/yr

Associate Director, Data Architect

Amylyx PharmaceuticalsAmylyx Pharmaceuticals
Cambridge, MA
1w ago
$190K - $206K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 6,314 patients
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.